JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6226
Black Diamond Therapeutics
BDTX
$109M
| $1K | ﹤0.01% |
552
| – | – |
2020 Q1
12 quarters
|
|
|
BGI
6227
DELISTED
Birks Group
BGI
| $1K | ﹤0.01% |
+100
| New | +$782 |
2023 Q1
0 quarters
|
|
6228
BGSF Inc
BGSF
$52.5M
| $1K | ﹤0.01% |
81
+67
| +479% | +$935 |
2016 Q4
25 quarters
|
|
6229
Innovator US Equity Buffer ETF January
BJAN
$351M
| $1K | ﹤0.01% |
17
-103
| -86% | -$3.54K |
2022 Q4
1 quarter
|
|
6230
Barnes & Noble Education
BNED
$406M
| $1K | ﹤0.01% |
6
-60
| -91% | -$12.1K |
2015 Q3
30 quarters
|
|
6231
Santander
BSBR
$40.4B
| $1K | ﹤0.01% |
+112
| New | +$606 |
2023 Q1
0 quarters
|
|
|
BSJP
6232
DELISTED
Invesco BulletShares 2025 High Yield Corporate Bond ETF
BSJP
| $1K | ﹤0.01% |
42
-27
| -39% | -$604 |
2022 Q1
4 quarters
|
|
|
BSL
6233
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$169M
| $1K | ﹤0.01% |
50
-273
| -85% | -$3.52K |
2022 Q4
1 quarter
|
|
|
BWG
6234
BrandywineGLOBAL Global Income Opportunities Fund
BWG
$116M
| $1K | ﹤0.01% |
+103
| New | +$846 |
2023 Q1
0 quarters
|
|
6235
State Street SPDR Bloomberg Short Term International Treasury Bond ETF
BWZ
$321M
| $1K | ﹤0.01% |
43
+40
| +1,333% | +$1.08K |
2022 Q4
1 quarter
|
|
|
CARM
6236
DELISTED
Carisma Therapeutics
CARM
| $1K | ﹤0.01% |
291
| – | – |
2021 Q2
7 quarters
|
|
|
CEV
6237
Eaton Vance California Municipal Income Trust
CEV
$73M
| $1K | ﹤0.01% |
+141
| New | +$1.44K |
2023 Q1
0 quarters
|
|
6238
Compass Therapeutics
CMPX
$154M
| $1K | ﹤0.01% |
+407
| New | +$1.6K |
2023 Q1
0 quarters
|
|
6239
ZW Data Action Technologies
CNET
$5.87M
| $1K | ﹤0.01% |
100
| – | – |
2018 Q4
17 quarters
|
|
6240
Corbus Pharmaceuticals
CRBP
$119M
| $1K | ﹤0.01% |
193
-1,254
| -87% | -$5.49K |
2017 Q4
21 quarters
|
|
6241
Cricut
CRCT
$1.37B
| $1K | ﹤0.01% |
139
| – | – |
2021 Q4
5 quarters
|
|
6242
Curis
CRIS
$1.95M
| $1K | ﹤0.01% |
5
-5
| -50% | -$1.32K |
2021 Q2
7 quarters
|
|
6243
CorMedix
CRMD
$560M
| $1K | ﹤0.01% |
195
| – | – |
2019 Q2
15 quarters
|
|
6244
Corvus Pharmaceuticals
CRVS
$917M
| $1K | ﹤0.01% |
1,201
| – | – |
2021 Q4
5 quarters
|
|
6245
Cytosorbents Corp
CTSO
$12.8M
| $1K | ﹤0.01% |
19
| – | – |
2018 Q2
19 quarters
|
|
6246
CEL-SCI Corp
CVM
$40.6M
| $1K | ﹤0.01% |
9
| – | – |
2019 Q2
15 quarters
|
|
|
CXE
6247
DELISTED
MFS High Income Municipal Trust
CXE
| $1K | ﹤0.01% |
191
-1,809
| -90% | -$6.49K |
2022 Q4
1 quarter
|
|
6248
Dianthus Therapeutics
DNTH
$4.93B
| $1K | ﹤0.01% |
44
| – | – |
2018 Q3
18 quarters
|
|
|
ETW
6249
Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund
ETW
$1.03B
| $1K | ﹤0.01% |
148
-22,476
| -99% | -$180K |
2022 Q4
1 quarter
|
|
6250
First Trust Global Wind Energy ETF
FAN
$200M
| $1K | ﹤0.01% |
50
-1,110
| -96% | -$19.7K |
2020 Q3
10 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.